Patents Examined by Matt Mauro
-
Patent number: 9808542Abstract: The present invention is directed to pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The invention further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.Type: GrantFiled: June 9, 2015Date of Patent: November 7, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Abbas W. Walji, Eric Hostetler, Thomas J. Greshock, Jing Li, Keith P. Moore, Idriss Bennacef, James Mulhearn, Harold Selnick, Yaode Wang, Kun Yang, Jianmin Fu
-
Patent number: 9809605Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.Type: GrantFiled: July 21, 2017Date of Patent: November 7, 2017Assignee: GLADIUS PHARMACEUTICALS CORPORATIONInventors: Larry Sutton, Sophia Yu
-
Patent number: 9809588Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.Type: GrantFiled: July 2, 2015Date of Patent: November 7, 2017Assignee: Board of Regents, The University of Texas SystemInventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
-
Patent number: 9809598Abstract: Compounds of the formula I in which W, X and Y have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.Type: GrantFiled: April 16, 2015Date of Patent: November 7, 2017Assignee: MERCK PATENT GMBHInventors: Hans-Peter Buchstaller, Dieter Dorsch
-
Patent number: 9809564Abstract: The present invention is related to a thermal extract of a plant material and methods of extraction thereof. The method of producing a thermal extract from a plant starting material by means of a thermal extraction of the starting material wherein the improvement consists in requiring smaller amounts of costly and/or toxic organic solvents for the extraction and partitioning steps.Type: GrantFiled: July 29, 2015Date of Patent: November 7, 2017Assignee: Pharmatherm Chemicals, Inc.Inventors: David Boulard, Robert G. Graham, Barry A. Freel
-
Patent number: 9809822Abstract: Tripyolide-nucleic acid aptamer derivatives, a preparation method and use thereof are shown. The structure of the triptolide-nucleic acid aptamer derivatives is as shown by formula I, wherein the definitions of R1-R7, G, A, B, M, Z and X are described. The present invention uses a nucleic acid aptamer and triptolide or modified compounds thereof as the starting materials, and introduces a linking group A at the C-14 hydroxyl group, epoxy groups and five-membered ring lactones in triptolide, then connects it to a nucleic acid aptamer B, and obtains the triptolide-nucleic acid aptamer derivatives. The triptolide-nucleic acid aptamer derivatives of the present invention have the characteristics of good targeting, a high anti-cancer activity, low toxicity and side effects, good water solubility and high bioavailability, and the preparation method of the present invention is scientific and reasonable and has a controllable quality and good repeatability, and is thereby suitable for production.Type: GrantFiled: December 11, 2013Date of Patent: November 7, 2017Assignee: HONG KONG BAPTIST UNIVERSITYInventors: Ge Zhang, Aiping Lu, Cheng Wang, Cheng Lu, Jun Lu, Biao Liu
-
Patent number: 9808449Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.Type: GrantFiled: December 23, 2015Date of Patent: November 7, 2017Assignee: BIOGEN MA INC.Inventors: Jermaine Thomas, Sha Mi, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin Guckian, Gnanasambandam Kumaravel
-
Patent number: 9802968Abstract: The present invention describes branched and functionalized siloxanes and methods for making such compounds. The compounds have a variety of uses. One preferred application is as novel planarizing material for lithogaphy, in which case functionalized branched siloxane, such as an epoxy-modified branched siloxane is particularly useful.Type: GrantFiled: August 9, 2016Date of Patent: October 31, 2017Assignee: Board of Regents, The University of Texas SystemInventors: C. Grant Willson, Tsuyoshi Ogawa, Michael B Jacobsson
-
Patent number: 9802909Abstract: An enantioselective process for the synthesis of (+)-petromyroxol and its Diastereomers from (3aR,5R,6aR)-2,2-dimethyl-5-((R)-oxiran-2-yl)tetrahydrofuro[2,3-d][1,3]dioxole.Type: GrantFiled: March 17, 2016Date of Patent: October 31, 2017Assignee: Council of Scientific & Industrial ResearchInventors: Chepuri Venkata Ramana, Venkannababu Mullapudi
-
Patent number: 9801849Abstract: This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.Type: GrantFiled: November 9, 2016Date of Patent: October 31, 2017Assignee: Corbus Pharmaceuticals, Inc.Inventor: Mark Tepper
-
Patent number: 9758501Abstract: The present invention discloses the syntheses of new 3-hydroxyflavone salts with defined structures, which are suitable for sensor applications for sensing anions, cations, DNA chains and organic compounds soluble in highly polar solvent like water.Type: GrantFiled: October 10, 2013Date of Patent: September 12, 2017Assignee: TUBITAK (TURKIYE BILIMSEL VE TEKNOLOJIK ARASTIRMA KURUMU)Inventors: Turan Ozturk, Mehmet Saip Eroglu, Asli Capan, Muslum Akgoz
-
Patent number: 9745328Abstract: The present invention relates to compounds of Formula (I), or a form thereof wherein ring A1, R1, R2, R3, R3?, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.Type: GrantFiled: January 31, 2014Date of Patent: August 29, 2017Assignee: Janssen Pharmaceutica NVInventors: Genesis M. Bacani, Wendy Eccles, Anne E. Fitzgerald, Steven D. Goldberg, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Alice Lee-Dutra, Jing Liu, Kelly J. McClure, Steven P. Meduna, Daniel J. Pippel, Mark D. Rosen, Zachary S. Sales
-
Patent number: 9732084Abstract: Pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position on one monomer unit, and a C2-C3 double bond and either a conjugated double or triple bond at the C2 position or an alkyl group at the C2 position on the other monomer unit, and conjugates of these compounds.Type: GrantFiled: November 6, 2013Date of Patent: August 15, 2017Assignees: Medimmune Limited, Seattle Genetics Inc.Inventors: Philip Wilson Howard, Luke Masterson, Arnaud Tiberghien, Scott Jeffrey, Patrick Burke, Peter Senter
-
Patent number: 9725460Abstract: Certain embodiments are directed to oridonin analogs or derivatives. In certain aspects, the derivatives are used as anticancer or anti-inflammatory agents.Type: GrantFiled: October 5, 2015Date of Patent: August 8, 2017Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Jia Zhou, Chunyong Ding, Qiang Shen
-
Patent number: 9718798Abstract: Provided are solid forms of 5-(halomethyl)furfural, including a crystalline form of 5-(chloromethyl)furfural. Provided are also methods for preparing solid forms of 5-(halomethyl)furfural by crystallization using certain solvents.Type: GrantFiled: September 11, 2015Date of Patent: August 1, 2017Assignee: MICROMIDAS, INC.Inventors: Shawn M. Browning, Makoto N. Masuno, John Bissell, II, Benjamin F. Nicholson
-
Patent number: 9717706Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.Type: GrantFiled: August 14, 2015Date of Patent: August 1, 2017Assignee: Nivalis Therapeutics, Inc.Inventors: Xicheng Sun, Jian Qiu, Jan Wasley
-
Patent number: 9718797Abstract: Disclosed are methods for preparing a mixture of eight diasteromers of vittatalactone Also disclosed are mixtures of eight diasteromers of vittatalactone produced by the methods described herein. In addition there are described compositions comprising a mixture of eight diasteromers of vittatalactone and optionally (2E,6Z)-nona-2,6-dienal and optionally cucurbitacin B or cucurbitacin B, and optionally a carrier. Furthermore, there are describe methods of attracting Acalymma vittatum to an object or area, involving treating said object or area with a Acalymma vittatum attracting composition containing a Acalymma vittatum attracting effective amount of the compositions described herein.Type: GrantFiled: August 20, 2015Date of Patent: August 1, 2017Assignees: The United States of America, as Represented by the Secretary of Agirculture, Chemveda Life Sciences, Inc.Inventors: Kamlesh R. Chauhan, Bheema R. Paraselli
-
Patent number: 9718814Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.Type: GrantFiled: July 6, 2016Date of Patent: August 1, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Shigemitsu Matsumoto, Yasushi Hattori, Masashi Toyofuku, Shinji Morimoto, Takuto Kojima, Tomohiro Kaku, Mitsuhiro Ito
-
Patent number: 9714241Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.Type: GrantFiled: July 6, 2016Date of Patent: July 25, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Shigemitsu Matsumoto, Yasushi Hattori, Masashi Toyofuku, Shinji Morimoto, Takuto Kojima, Tomohiro Kaku, Mitsuhiro Ito
-
Patent number: 9708321Abstract: The present invention relates to novel spiro-quinazolinone derivatives as positive allosteric modulators for modulating metabotropic glutamate receptor subtype 4 (mGluR4) and/or altering glutamate level or glutamatergic signalling.Type: GrantFiled: January 23, 2014Date of Patent: July 18, 2017Assignee: MERCK PATENT GMBHInventors: Nadia Brugger, Brian L. Hodous, Amanda E. Sutton, Justin Potnick, Theresa L. Johnson, Thomas E. Richardson, Thomas Francis Nelson Haxell, James M. Dorsey, Robert James Foglesong